Delving into the Latest Updates on Zhejiang Haibo Biotechnology Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Contrast agent

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

No Data

Disease Domain	Count

Neoplasms	1

Top 5 Drug Type	Count

Contrast agent	1
Small molecule drug	1

Evaluate the safety and tolerability of a single intravenous injection of NC527-X; determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) of NC527-X for injection. Evaluate the pharmacokinetic (PK) characteristics of NC527-X for injection. Evaluate other safety of a single intravenous injection of NC527-X.

Start Date-

Sponsor / Collaborator

Zhejiang Haibo Biotechnology Co., Ltd.

100 Clinical Results associated with Zhejiang Haibo Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Zhejiang Haibo Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Zhejiang Haibo Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Zhejiang Haibo Biotechnology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Jul 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1

1

Login to view more data